PROFID has been presented at the ESC Congress 2023 in Amsterdam. With 30,000 participants, this is the world’s largest cardiovascular congress, and we had the opportunity to meet top cardiology experts and further increase awareness of the PROFID project.
During the congress, we focused especially on the upcoming trial, as those results are anticipated to change the prevention of sudden cardiac death in clinical practice.
We therefore organised a meeting with the Steering Committee and the National Coordinators of the trial. It is a privilege to meet these so supportive and experienced partners in person and always leads to fruitful discussions and important advice. In addition, we hold our 2nd Investigators Meeting in order to inform potentially participating study sites about the upcoming trial and to discuss any open questions or concerns.
This year these meetings were even more important as we announced with great pleasure a very positive and significant development in the PROFID trial. We have been given the opportunity for an even closer collaboration with the EHRA (European Heart Rhythm Association). EHRA, as part of the European Society of Cardiology (ESC), highly supports the PROFID project and the trial and is a consortium partner via the ESC. In close alignment with the EHRA leadership, the EHRA board and the ESC leadership, we further strengthened the strategic cooperation between PROFID and EHRA by modifying the acronym of the trial from “PROFID” to “PROFID EHRA” and including an EHRA representative in the Steering Committee of the trial. We are very happy that EHRA decided to nominate the current EHRA president, Professor Jose L. Merino as the EHRA representative in the Steering Committee of the trial. Prof. Merino greatly supports PROFID and is the National Coordinator of the trial in Spain. We are sure that this step will have substantial benefits for the trial, as it will significantly facilitate patient recruitment given the great trust of the cardiological community in EHRA and the ESC. The ESC Congress 2023 in Amsterdam gave us the opportunity to highlight this important development.
Besides our meetings, we also had the opportunity to prominently feature PROFID and the renamed PROFID EHRA trial in an ESC TV interview session with the Principal Investigators of the trial, Prof. Gerhard Hindricks and Dr. Nikolaos Dagres, as well as the project manager of the clinical research organisation of the trial, Dr. Raphaela Kübeck.
We would like to thank ESC for a great ESC 2023 Congress and all who attended our sessions!